α2-adrenergic receptors in platelet membranes of depressed patients: No change in number of 3H-yohimbine affinity

Daiguji, Makoto; Meltzer, Herbert Y.; Tong, Ching; U’Prichard, David C.; Young, Michael; Kravitz, Howard M.

doi:10.1016/0024-3205(81)90662-7

Cited by 77 publications

(5 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lack of difference in platelet [ 3 H]yohimbine binding between depressed patients and controls is in accord with other studies using this ligand or its isomer (Daiguji et al 1981;Pimoule et al 1983;Stahlefa/. 1983;Campbell etal.…”

Section: Discussionsupporting

confidence: 89%

“…However, Healey et al (1983) found DHE binding to be increased in depressed subjects. Studies of binding of [ 3 H]yohimbine or its isomer [ 3 H]rauwolscine to platelet membranes have found no difference between depressed and control subjects (Daiguji et al 1981;Pimoule et al 1983;Stahl et al 1983;Campbell et al 765 1985). Garcia-Sevilla et al (1981), using the alpha-2-agonist clonidine, reported both highand low-affinity binding for this ligand to platelet membranes; high affinity binding was increased in depressed patients compared with controls.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Binding of yohimbine and imipramine to platelets in depressive illness

et al. 1986

View full text Add to dashboard Cite

SynopsisRadioligand binding to intact platelets was carried out in antidepressant-free patients and the 1 mg dexamethasone suppression test (DST) was performed. There were no differences in binding characteristics between patients and controls for either [H]yohimbine or [H]imipramine. There were no differences in binding between patients classified as endogenous using the Newcastle Scale, compared with non-endogenous patients, and no difference between DST suppressors and non-suppressors. The severity of depression did not affect binding values. After 4–6 weeks antidepressant treatment [H]yohimbine binding was significantly reduced but [H]imipramine binding was unaffected.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Introductionmentioning

confidence: 99%

Binding of yohimbine and imipramine to platelets in depressive illness

et al. 1986

View full text Add to dashboard Cite

show abstract

“…The results of studies in which 3 H-clonidine, an agonist, was employed, have shown an increased density of alpha 2-adrenoreceptors in depressed patients, as compared with controls, especially in those with an early onset of the illness and with low MHPG excretion (Garcia-Sevilla et al, 1981;; on the other hand, with 3 H-UK-14,304, another agonist, no difference was detected (Theodoru et al, 1986). In addition, no difference between patients and controls was found with the selective antagonists 3 Hrauwolscine or 3 H-yohimbine (Daiguji et al, 1981;Pimoule et al, 1983;Braddock er o/, 1986), whereas data with the non-selective antagonist 3 Hdihydroergotamine are controversial (Wood and Coppen, 1981;Kafka et al, 1983).…”

Section: Human Datamentioning

confidence: 99%

Is depression a disorder of a receptor superfamily? A critical review of the receptor theory of depression and the appraisal of a new heuristic model

Cassano

Marazziti

1992

Eur. psychiatr.

View full text Add to dashboard Cite

SummaryThe monoamine hypothesis of depression and its direct derivation, the receptor theory, have constituted for several years a frame of reference for researchers working in the field of biological psychiatry. Although most of the data are derived from animal findings and must be considered inconclusive in view of various controversies, some guidelines may be identified: these would suggest that changes in postsynaptic beta-adrenoreceptors, presynaptic alpha 2-adrenoreceptors, as well as in type 2 serotonin receptors and dopaminergic autoreceptors may be involved in the mode of action of antidepressant drugs and, consequently, in the pathophysiology of depression. Nowadays, any attempt to correlate depression with the dysfunction of a single neurotransmitter or receptor is no longer tenable, since it is clear that depression is a heterogeneous disorder which involves abnormalities in the interactive relationships between neurotransmitters and receptors. If, on the one hand, this new model has opened up new fields of research and has led to the investigation of new systems, eg the GABAergic and GABA B receptors, on the other hand, it has been strongly limited by the lack of research tools and reliable peripheral CNS models for in vivo studies. A possible approach to this unresolved dilemma may be provided by molecular biology techniques, which have permitted the identification of the genes and sequencing of the primary structure of several membrane receptors. It is now established that receptors may be grouped into four superfamilies; in depression, there exists compelling evidence of alterations mainly in receptors belonging to the G-protein-coupled family: it is plausible that depression may be related to a disorder of the G-protein-coupled receptor superfamily. Such an hypothesis would represent an attempt to unify the different receptor abnormalities found in depression or following antidepressant treatments, and to shift from the monoamine paradigm to a new heuristic model. In addition, it would accommodate the various dysfunctions likely to be encountered and would open up new theoretical perspectives in the treatment of depression.

show abstract

“…u2-adrenergic agonists bind to the high affinity state of the receptor (HoJJman et al, 1980;Lynch and Steer, 1981), suggesting that in depressed patients it is primarily the high affinity platelet u2-adrenergic receptor sites that are e1evated. Using the less selective antagonist 3H-dihydroergocryptine or the u2-adrenergic selective antagonists 3H-yohimbine and 3H-rauwolscine as ligands, the data are less consistent, as some groups found elevated, (Kajka et al, 1980Healy et al , 1983;Siever et al, 1984;Roy and Kajka, 1989) unaltered, (Daiguji et al, 1981;Lenox et al , 1983;Smith et al, 1983;Pimoule et al, 1983;Siever et al, 1983;Campbell et al, 1985;Wolfe et al, 1987;Katona et al, 1989) or decreased (Wood andCoppen. 1982, 1983;Wood et al, 1985) receptor sites.…”

Section: Die Wirkung Von Desipramin Auf Die Thrombozyten-bindungsparamentioning

confidence: 99%

Platelet α₂-Adrenergic Receptors in Depressed Patients and Healthy Volunteers: The Effects of Desipramine

Werstiuk

Auffarth²,

Coote³

et al. 1992

Pharmacopsychiatry

View full text Add to dashboard Cite

Binding parameters (Bmax and Kd) of alpha 2-adrenergic receptors were studied in platelets from 14 depressed patients and 18 control subjects. Using 3H-clonidine (a partial alpha 2-adrenergic agonist) as the ligand and membranes, prepared from platelets isolated under physiological conditions, we found no significant differences in Bmax and Kd between medication free patients and control subjects. Platelet binding parameters in the depressed patients did not correlate with plasma levels of norepinephrine, epinephrine or MHPG. Age had a significant positive effect on platelet alpha 2-adrenergic receptor Bmax in both groups, and may have masked the patient-control differences. Treatment with desipramine for 28 days had no effect on the binding parameters in depressed patients when compared to pretreatment values. Adding desipramine to platelets of control subjects 'in vitro' did also not affect binding parameters. Our findings suggest that receptor binding studies with a partial alpha 2-adrenergic agonist in platelet membranes are not a useful model to test the hypothesis of a central supersensitive adrenergic system in depression.

show abstract

α2-adrenergic receptors in platelet membranes of depressed patients: No change in number of 3H-yohimbine affinity

Cited by 77 publications

References 28 publications

Binding of yohimbine and imipramine to platelets in depressive illness

Binding of yohimbine and imipramine to platelets in depressive illness

Is depression a disorder of a receptor superfamily? A critical review of the receptor theory of depression and the appraisal of a new heuristic model

Platelet α₂-Adrenergic Receptors in Depressed Patients and Healthy Volunteers: The Effects of Desipramine

Contact Info

Product

Resources

About

α2-adrenergic receptors in platelet membranes of depressed patients: No change in number of 3H-yohimbine affinity

Cited by 77 publications

References 28 publications

Binding of yohimbine and imipramine to platelets in depressive illness

Binding of yohimbine and imipramine to platelets in depressive illness

Is depression a disorder of a receptor superfamily? A critical review of the receptor theory of depression and the appraisal of a new heuristic model

Platelet α2-Adrenergic Receptors in Depressed Patients and Healthy Volunteers: The Effects of Desipramine

Contact Info

Product

Resources

About

Platelet α₂-Adrenergic Receptors in Depressed Patients and Healthy Volunteers: The Effects of Desipramine